Commercial Partner for Aseptic Services
Description: The Founding NHS Trusts seek a commercial partner to establish an innovative company to design, build, commission, and operate a purpose-built MHRA-licensed aseptic manufacturing facility serving the West Midlands region. The Founding NHS Trusts would be an associate having significant control. This partnership will address critical regional infrastructure challenges where aging NHS facilities require significant capital investment. The model would seek to leverage commercial capital (PS20 million+) and operational expertise while maintaining NHS clinical governance and providing founding trusts with at-cost services. Chemotherapy and cytotoxic preparations CIVAS (Centralised Intravenous Additive Services) OPAT (Outpatient Parenteral Antimicrobial Therapy) Non-cytotoxic monoclonal antibodies Advanced Therapy Medicinal Products (ATMPs) Other sterile preparations (intrathecal, intra-articular, epidural, ophthalmic) Excluded: Radiopharmaceuticals, Clinical trial/IMP preparation The Founding NHS Trusts intend to conduct Preliminary Market Engagement following publication (read more...)
Summary: The Worcestershire Acute Hospitals NHS Trust, in collaboration with multiple NHS Trusts in the West Midlands, invites expressions of interest for a commercial partnership aimed at establishing a cutting-edge, MHRA-licensed aseptic manufacturing facility. The initiative is currently in the planning stage, with preliminary market engagement sessions scheduled for 7th and 9th January 2026. Potential suppliers with capabilities in aseptic compounding are encouraged to participate. The project encompasses a wide scope within the pharmaceutical services, with a procurement value exceeding £290 million and spans major categories such as pharmacy services, pharmaceutical products, and construction and engineering services, across various regions in the United Kingdom.